Insider Selling: Teva Pharmaceutical Industries Ltd (NYSE:TEVA) CFO Sells 1,406 Shares of Stock

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) CFO Michael James Mcclellan sold 1,406 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $7.83, for a total value of $11,008.98. Following the sale, the chief financial officer now owns 16,851 shares of the company’s stock, valued at approximately $131,943.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

TEVA traded up $0.16 on Friday, hitting $6.90. 12,457,081 shares of the company were exchanged, compared to its average volume of 14,815,792. The firm has a fifty day simple moving average of $7.16 and a two-hundred day simple moving average of $9.89. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96. Teva Pharmaceutical Industries Ltd has a 12 month low of $6.07 and a 12 month high of $23.97. The stock has a market capitalization of $7.14 billion, a PE ratio of 2.46, a price-to-earnings-growth ratio of 0.69 and a beta of 1.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.02. The business had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. Teva Pharmaceutical Industries’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same period last year, the company earned $0.78 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current year.

TEVA has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on Teva Pharmaceutical Industries in a research note on Thursday, September 12th. They issued a “neutral” rating for the company. Wells Fargo & Co reduced their price objective on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating for the company in a research note on Monday, September 30th. Morgan Stanley downgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $16.00 to $6.00 in a research note on Monday, July 15th. Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Friday, July 5th. Finally, JPMorgan Chase & Co. dropped their price target on Teva Pharmaceutical Industries from $9.00 to $7.00 and set an “underweight” rating on the stock in a research report on Friday, September 6th. Six equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have given a buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average target price of $11.17.

Several hedge funds have recently modified their holdings of TEVA. Renaissance Technologies LLC lifted its stake in shares of Teva Pharmaceutical Industries by 272.6% in the 2nd quarter. Renaissance Technologies LLC now owns 9,786,063 shares of the company’s stock valued at $90,325,000 after purchasing an additional 7,159,900 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Teva Pharmaceutical Industries by 20.0% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 9,553,328 shares of the company’s stock valued at $88,177,000 after purchasing an additional 1,593,139 shares during the period. Northern Trust Corp lifted its stake in shares of Teva Pharmaceutical Industries by 12.5% in the 2nd quarter. Northern Trust Corp now owns 7,610,010 shares of the company’s stock valued at $70,239,000 after purchasing an additional 846,650 shares during the period. Camber Capital Management LP raised its stake in Teva Pharmaceutical Industries by 85.7% during the second quarter. Camber Capital Management LP now owns 6,500,000 shares of the company’s stock valued at $59,995,000 after buying an additional 3,000,000 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its stake in Teva Pharmaceutical Industries by 0.5% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,348,213 shares of the company’s stock valued at $49,364,000 after buying an additional 26,600 shares during the last quarter. Hedge funds and other institutional investors own 57.78% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: Day Trading – Risk Worth the Reward?

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.